Building HEALTHIER FUTURES
powered by THOUGHTFUL SCIENCE

We are a highly focused, research-driven biopharmaceutical company working in rare diseases. Our current goal is to optimize the potential of exon-skipping therapy in treating Duchenne muscular dystrophy (DMD).

Inspired by our own families, as well as the individuals we aim to provide with treatment, NS Pharma is conducting advanced research in rare diseases, including exon-skipping technology, to offer new, effective treatment options for DMD.

PRESS RELEASES